PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Both yoy net incomes decline, with AXSM at -27.22%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
8.11%
Less D&A growth vs. AXSM's 1008.95%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
14.88%
Some yoy growth while AXSM is negative at -100.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
33.33%
Less SBC growth vs. AXSM's 95.41%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-359.86%
Both reduce yoy usage, with AXSM at -10.06%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Both reduce yoy usage, with AXSM at -54.16%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-14.88%
Negative yoy while AXSM is 126.81%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-25.31%
Both yoy CFO lines are negative, with AXSM at -30.63%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-2962.50%
Both yoy lines negative, with AXSM at -36.66%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
Both yoy lines negative, with AXSM at -36.66%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
56.30%
Debt repayment growth of 56.30% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
23135.79%
Issuance growth of 23135.79% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
100.00%
Buyback growth of 100.00% while AXSM is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.